Noninterventional follow-up vs fluid bolus in RESPONSE to oliguria-The RESPONSE trial protocol and statistical analysis plan

Acta Anaesthesiol Scand. 2020 Sep;64(8):1210-1217. doi: 10.1111/aas.13599. Epub 2020 Apr 28.

Abstract

Background: Oliguria is a frequent trigger for administering a fluid bolus, but the effect of fluid bolus in improving urine output is inadequately demonstrated. Here, we summarize the protocol and detailed statistical analysis plan of the randomized, controlled RESPONSE trial comparing follow-up as the experimental group and a 500 mL crystalloid fluid bolus as the control group for oliguria in critically ill oliguric patients.

Methods: Our trial is an investigator-initiated, randomized, controlled, pilot trial conducted in three ICUs in two centers. We aim to randomize 1:1 altogether 130 hemodynamically stable oliguric patients either to a 2-hour follow-up without interventions or to receive a crystalloid bolus of 500 mL over 30 minutes. The primary outcome is the change in individual urine output during the 2-hour period compared to 2 hours preceding randomization. Doubling of the urine output is considered clinically significant. Additionally, we record the duration of oliguria, physiological and biochemical variables, adverse events, and the incidences of acute kidney injury and renal replacement therapy.

Conclusions: Oliguria is a frequent trigger for potentially harmful fluid loading. Therefore, the RESPONSE trial will give information of the potential effect of fluid bolus on oliguria in critically ill patients.

Trial registration: clinical.trials.gov, NCT02860572.

Keywords: acute kidney injury; critically ill; fluid bolus; oliguria.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Clinical Protocols*
  • Critical Care / methods
  • Critical Illness
  • Crystalloid Solutions / therapeutic use*
  • Finland
  • Fluid Therapy / methods*
  • Fluid Therapy / statistics & numerical data*
  • Follow-Up Studies
  • Humans
  • Oliguria / therapy*
  • Pilot Projects
  • Research Design*
  • Time Factors
  • Treatment Outcome
  • Young Adult

Substances

  • Crystalloid Solutions

Associated data

  • ClinicalTrials.gov/NCT02860572